Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Linda Pearson who wrote (137)	12/2/1997 7:19:00 PM
From: W. Clinton Terry	Respond to of 942

Linda: Do you have time to talk about WLA? Would be helpful. Won't take up your time if you busy now. Clinton

To: Linda Pearson who wrote (137)	12/2/1997 8:32:00 PM
From: Ted Downs	Read Replies (2) \| Respond to of 942

Linda, From the Lancaster New Era newspaper Dec 2, 1997. Large article on WLA since WLA plant is located in county. I quote " Warner Lambert, which has a major plant in Lititz, said Glaxo Wellcome overreacted. Warner Lambert added that it will keep selling the drug in the U.S.The FDA and Warner-Lambert first disclosed the concern about Rezulin on Nov.3, after getting 35 reports of liver failure that leg to one death and another person needing a liver transplant. The FDA asked for additional reports on adverse reactions to the drug. The agency has now received a total of 150 adverse event reports, including three deaths from liver failure linked to the drug in Japan. The FDA saying about 600,000 patients in the U.S. and 200,000 in Japan take Rezulin , assured patients that the benefits of taking the drug outweigh the risks. "